Saracatinib, a selective Src kinase inhibitor is analysed in the STOP-FOP trial https://t.co/SxwOfzV9uB, but also blocks fibrotic responses in preclinical models of pulmonary fibrosis https://t.co/DY27kaSYTy and will be evaluated in the placebo controlled
192 followers
1,500 followers
Smilde et al: Protocol paper: a multi-center, double-blinded, randomized, 6-month, placebo-controlled study followed by 12-month open label extension to evaluate the safety and efficacy of Saracatinib in Fibrodysplasia Ossificans Progressiva (STOPFOP) http
1,500 followers
Smilde et al: Protocol paper: a multi-center, double-blinded, randomized, 6-month, placebo-controlled study followed by 12-month open label extension to evaluate the safety and efficacy of Saracatinib in Fibrodysplasia Ossificans Progressiva (STOPFOP) http
44 followers
The STOPFOP team is committed to open science. We are therefore happy to report that our protocol paper has just been published 😃It can be found at: https://t.co/HMKt6BdE77 #cureFOP #RareDisease